A Study of AL2846 Capsule Combined With Standard Chemotherapy Regimen in Subjects With Advanced Colorectal Cancer
This is a study to explore the safety, tolerance and efficacy of AL2846 capsules combined with mFOLFOLX6 or FOLFIRI standard chemotherapy regimen in subjects with advanced metastatic colorectal cancer.
Advanced Colorectal Cancer
DRUG: AL2846|DRUG: Calcium folate|DRUG: 5-FU|DRUG: Oxaliplatin|DRUG: Irinotecan
Progression-free survival (PFS), PFS defined as the time from the first dose until the first documented progressive disease (PD) or death from any cause, based on investigator., up to 12 month
Overall response rate (ORR), Percentage of participants achieving complete response (CR) and partial response (PR)., up to 12 month|Disease control rate（DCR）, Percentage of participants achieving complete response (CR) and partial response (PR) and stable disease (SD)., up to 12 month|Duration of response (DOR), The time when the participants first achieved complete or partial remission to disease progression., up to 12 month
This is a study to explore the safety, tolerance and efficacy of AL2846 capsules combined with mFOLFOLX6 or FOLFIRI standard chemotherapy regimen in subjects with advanced metastatic colorectal cancer.